Somatostatin Receptor Type 4 Market by Type (NTX-0290, NNC-26910, Veldoreotide), by Application (Chronic Pain, Acromegaly, Neuropathic Pain, Alzheimer’s Disease, Cognitive Disorder, Dementia, Diabetic Retinopathy, Gastrointestinal Tumor, Neuroendocrine Tumors, Pancreatic Tumor, Pituitary ACTH Hypersecretion); by Regional outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018 - 2026

Report ID :AMI-121 | Category : Therapeutic Area | Published Date :August, 2018 | Pages : 187 | Format :PDF
Buy Now!

Industry Trends

Somatostatin Receptor Type 4, encoded as SSTR4 in humans, is a gene on chromosome 20p11.2 that encodes a G protein-coupled somatostatin receptor for somatostatin-14. SSTR4 is specifically expressed in pituitary and pancreas in addition to the brain. It is responsible for mediating antiproliferative action of somatostatin in tumor cells. The advancement of sophisticated analytical techniques and isolation technologies is making extraction and application of SSTR4 possible for multiple diseases. Some of the diseases include acromegaly, gastrointestinal tumor, cognitive disorders, pancreatic tumor among others.

Somatostatin Receptor Type 4 Market

As somatostatin and its analogs are capable of varied actions, their potential in contribution to cancer diagnosis and treatment via multiple mechanisms is being explored. The inhibition of the hormonal hypersecretion often provides symptomatic relief and tumor shrinkage occurs in some patients. Hence, somatostatin is well-established in the treatment of pituitary tumors and neuroendocrine tumors of the pancreas and gastrointestinal tract. Owing to the demand for SSTR4 assays over numerous therapeutic areas, pharmaceutical companies are investing in research & development to explore the vast possibilities of somatostatin receptor type 4.

Somatostatin Receptor Type 4, By Application

The application of SSTR4 is anticipated to capture the highest market in chronic pain. The somatostatin receptor type 4 market by chronic pain was valued at US$ 193.5 Mn in 2016 expanding at a CAGR of 8.0 % from 2017 to 2025. The rise in cases of chronic pain is not specific but can stem from imbalanced sleep, fatigue, decreased appetite and mood changes. Somatostatin inhibits nociceptive combined with inflammatory processes via the SSTR4 pathway. Somatostatin alleviates pain even in cases when opioids fail and has an important role in neuromodulations such as pain control. 

Somatostatin Receptor Type 4, By Region

North America exhibits an upper hand in consumption and demand of Somatostatin Receptor Type 4. Increasing incidences of lifestyle diseases in the region as well as affordability for treatment is propelling the market. The most common assays include cAMP assays, radioligand binding assays and metabolic stability assays. The availability of skilled technicians and workforce resulting from good education and training institutes is also aiding the growth of the somatostatin receptor type 4 market in the region.

Competitive Landscape

The report provides both, qualitative and quantitative research of the market, as well as integrates worthy insights into the rational scenario and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers & acquisitions (M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the somatostatin receptor type 4 market report. For each company, the report recognizes their corporate headquarter, competitors, product/service type, application and specification, pricing, and gross margin.

Some of the primary market participants are Centrexion Therapeutics, CRINETICS PHARMACEUTICALS and Strongbridge Biopharma plc amongst others.

Global Somatostatin Receptor Type 4 Industry Background

Somatostatin Receptor Type 4 MarketSomatostatin Receptor Type 4 Market

1.    Introduction

1.1.   Market Scope

1.2.   Market Segmentation

1.3.   Methodology

1.4.   Assumptions

2.    Somatostatin Receptor Type 4 Market Snapshot

3.    Executive Summary: Somatostatin Receptor Type 4 Market

4.    Qualitative Analysis: Somatostatin Receptor Type 4 Market

4.1.   Introduction

4.1.1.   Product Definition

4.1.2.   Industry Development

4.2.   Market Dynamics

4.2.1.   Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.3.   Trends in Market

5.    Global Somatostatin Receptor Type 4 Market Analysis and Forecasts, 2018 – 2026

5.1.   Overview

5.1.1.   Global Market Revenue (US$ Mn) and Forecasts

5.2.   Global Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

5.2.1.   CNTX-0290

5.2.1.1.    Definition

5.2.1.2.    Market Penetration

5.2.1.3.    Market Revenue Expected to Increase by 2026

5.2.1.4.    Compound Annual Growth Rate (CAGR)

5.2.2.   NNC-26910

5.2.2.1.    Definition

5.2.2.2.    Market Penetration

5.2.2.3.    Market Revenue Expected to Increase by 2026

5.2.2.4.    Compound Annual Growth Rate (CAGR)

5.2.3.    Veldoreotide

5.2.3.1.    Definition

5.2.3.2.    Market Penetration

5.2.3.3.    Market Revenue Expected to Increase by 2026

5.2.3.4.    Compound Annual Growth Rate (CAGR)

5.3.   Key Segment for Channeling Investments

5.3.1.   By Type

6.    Global Somatostatin Receptor Type 4 Market Analysis and Forecasts, 2018 – 2026

6.1.   Overview

6.2.   Global Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

6.2.1.   Chronic Pain

6.2.1.1.    Definition

6.2.1.2.    Market Penetration

6.2.1.3.    Market Revenue Expected to Increase by 2026

6.2.1.4.    Compound Annual Growth Rate (CAGR)

6.2.2.   Acromegaly            

6.2.2.1.    Definition

6.2.2.2.    Market Penetration

6.2.2.3.    Market Revenue Expected to Increase by 2026

6.2.2.4.    Compound Annual Growth Rate (CAGR)

6.2.3.     Neuropathic Pain

6.2.3.1.    Definition

6.2.3.2.    Market Penetration

6.2.3.3.    Market Revenue Expected to Increase by 2026

6.2.3.4.    Compound Annual Growth Rate (CAGR)

6.2.4.   Alzheimer’s Disease

6.2.4.1.    Definition

6.2.4.2.    Market Penetration

6.2.4.3.    Market Revenue Expected to Increase by 2026

6.2.4.4.    Compound Annual Growth Rate (CAGR)

6.2.5.   Cognitive Disorder         

6.2.5.1.    Definition

6.2.5.2.    Market Penetration

6.2.5.3.    Market Revenue Expected to Increase by 2026

6.2.5.4.    Compound Annual Growth Rate (CAGR)

6.2.6.   Dementia            

6.2.6.1.    Definition

6.2.6.2.    Market Penetration

6.2.6.3.    Market Revenue Expected to Increase by 2026

6.2.6.4.    Compound Annual Growth Rate (CAGR)

6.2.7.   Diabetic Retinopathy              

6.2.7.1.    Definition

6.2.7.2.    Market Penetration

6.2.7.3.    Market Revenue Expected to Increase by 2026

6.2.7.4.    Compound Annual Growth Rate (CAGR)

6.2.8.   Gastrointestinal Tumor

6.2.8.1.    Definition

6.2.8.2.    Market Penetration

6.2.8.3.    Market Revenue Expected to Increase by 2026

6.2.8.4.    Compound Annual Growth Rate (CAGR)

6.2.9.   Neuroendocrine Tumors            

6.2.9.1.    Definition

6.2.9.2.    Market Penetration

6.2.9.3.    Market Revenue Expected to Increase by 2026

6.2.9.4.    Compound Annual Growth Rate (CAGR)

6.2.10. Pancreatic Tumor            

6.2.10.1.  Definition

6.2.10.2.  Market Penetration

6.2.10.3.  Market Revenue Expected to Increase by 2026

6.2.10.4.  Compound Annual Growth Rate (CAGR)

6.2.11. Pituitary ACTH Hypersecretion

6.2.11.1.  Definition

6.2.11.2.  Market Penetration

6.2.11.3.  Market Revenue Expected to Increase by 2026

6.2.11.4.  Compound Annual Growth Rate (CAGR)

6.3.   Key Segment for Channeling Investments

6.3.1.   By Application

7.    North America Somatostatin Receptor Type 4 Market Analysis and Forecasts, 2018 – 2026

7.1.   Overview

7.1.1.   North America Market Revenue (US$ Mn)

7.2.   North America Market Revenue (US$ Mn) and Forecasts, By Type

7.2.1.   CNTX-0290

7.2.2.   NNC-26910

7.2.3.    Veldoreotide

7.3.   North America Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

7.3.1.   Chronic Pain

7.3.2.   Acromegaly            

7.3.3.     Neuropathic Pain

7.3.4.   Alzheimer’s Disease

7.3.5.   Cognitive Disorder         

7.3.6.   Dementia            

7.3.7.   Diabetic Retinopathy              

7.3.8.   Gastrointestinal Tumor

7.3.9.   Neuroendocrine Tumors            

7.3.10. Pancreatic Tumor            

7.3.11. Pituitary ACTH Hypersecretion

7.4.   North America Market Revenue (US$ Mn) and Forecasts, By Country

7.4.1.   U.S.

7.4.1.1.    U.S. Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

7.4.1.1.1.    CNTX-0290

7.4.1.1.2.    NNC-26910

7.4.1.1.3.     Veldoreotide

7.4.1.2.    U.S. Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

7.4.1.2.1.    Chronic Pain

7.4.1.2.2.    Acromegaly            

7.4.1.2.3.      Neuropathic Pain

7.4.1.2.4.    Alzheimer’s Disease

7.4.1.2.5.    Cognitive Disorder         

7.4.1.2.6.    Dementia            

7.4.1.2.7.    Diabetic Retinopathy              

7.4.1.2.8.    Gastrointestinal Tumor

7.4.1.2.9.    Neuroendocrine Tumors            

7.4.1.2.10.  Pancreatic Tumor            

7.4.1.2.11.  Pituitary ACTH Hypersecretion

7.4.2.   Rest of North America

7.4.2.1.    Rest of North America Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

7.4.2.1.1.    CNTX-0290

7.4.2.1.2.    NNC-26910

7.4.2.1.3.     Veldoreotide

7.4.2.2.    Rest of North America Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

7.4.2.2.1.    Chronic Pain

7.4.2.2.2.    Acromegaly            

7.4.2.2.3.      Neuropathic Pain

7.4.2.2.4.    Alzheimer’s Disease

7.4.2.2.5.    Cognitive Disorder         

7.4.2.2.6.    Dementia            

7.4.2.2.7.    Diabetic Retinopathy              

7.4.2.2.8.    Gastrointestinal Tumor

7.4.2.2.9.    Neuroendocrine Tumors            

7.4.2.2.10.  Pancreatic Tumor            

7.4.2.2.11.  Pituitary ACTH Hypersecretion

7.5.   Key Segment for Channeling Investments

7.5.1.   By Country

7.5.2.   By Type

7.5.3.   By Application

8.    Europe Somatostatin Receptor Type 4 Market Analysis and Forecasts, 2018 – 2026

8.1.   Overview

8.1.1.   Europe Market Revenue (US$ Mn)

8.2.   Europe Market Revenue (US$ Mn) and Forecasts, By Type

8.2.1.   CNTX-0290

8.2.2.   NNC-26910

8.2.3.    Veldoreotide

8.3.   Europe Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

8.3.1.   Chronic Pain

8.3.2.   Acromegaly            

8.3.3.     Neuropathic Pain

8.3.4.   Alzheimer’s Disease

8.3.5.   Cognitive Disorder         

8.3.6.   Dementia            

8.3.7.   Diabetic Retinopathy              

8.3.8.   Gastrointestinal Tumor

8.3.9.   Neuroendocrine Tumors            

8.3.10. Pancreatic Tumor            

8.3.11. Pituitary ACTH Hypersecretion

8.4.   Europe Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Country

8.4.1.   France

8.4.1.1.    France Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

8.4.1.1.1.    CNTX-0290

8.4.1.1.2.    NNC-26910

8.4.1.1.3.     Veldoreotide

8.4.1.2.    France Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

8.4.1.2.1.    Chronic Pain

8.4.1.2.2.    Acromegaly            

8.4.1.2.3.      Neuropathic Pain

8.4.1.2.4.    Alzheimer’s Disease

8.4.1.2.5.    Cognitive Disorder         

8.4.1.2.6.    Dementia            

8.4.1.2.7.    Diabetic Retinopathy              

8.4.1.2.8.    Gastrointestinal Tumor

8.4.1.2.9.    Neuroendocrine Tumors            

8.4.1.2.10.  Pancreatic Tumor            

8.4.1.2.11.  Pituitary ACTH Hypersecretion

8.4.2.   The UK

8.4.2.1.    The UK Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

8.4.2.1.1.    CNTX-0290

8.4.2.1.2.    NNC-26910

8.4.2.1.3.     Veldoreotide

8.4.2.2.    The UK Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

8.4.2.2.1.    Chronic Pain

8.4.2.2.2.    Acromegaly            

8.4.2.2.3.      Neuropathic Pain

8.4.2.2.4.    Alzheimer’s Disease

8.4.2.2.5.    Cognitive Disorder         

8.4.2.2.6.    Dementia            

8.4.2.2.7.    Diabetic Retinopathy              

8.4.2.2.8.    Gastrointestinal Tumor

8.4.2.2.9.    Neuroendocrine Tumors            

8.4.2.2.10.  Pancreatic Tumor            

8.4.2.2.11.  Pituitary ACTH Hypersecretion

8.4.3.   Spain

8.4.3.1.    Spain Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

8.4.3.1.1.    CNTX-0290

8.4.3.1.2.    NNC-26910

8.4.3.1.3.     Veldoreotide

8.4.3.2.    Spain Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

8.4.3.2.1.    Chronic Pain

8.4.3.2.2.    Acromegaly            

8.4.3.2.3.      Neuropathic Pain

8.4.3.2.4.    Alzheimer’s Disease

8.4.3.2.5.    Cognitive Disorder         

8.4.3.2.6.    Dementia            

8.4.3.2.7.    Diabetic Retinopathy              

8.4.3.2.8.    Gastrointestinal Tumor

8.4.3.2.9.    Neuroendocrine Tumors            

8.4.3.2.10.  Pancreatic Tumor            

8.4.3.2.11.  Pituitary ACTH Hypersecretion

8.4.4.   Germany

8.4.4.1.    Germany Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

8.4.4.1.1.    CNTX-0290

8.4.4.1.2.    NNC-26910

8.4.4.1.3.     Veldoreotide

8.4.4.2.    Germany Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

8.4.4.2.1.    Chronic Pain

8.4.4.2.2.    Acromegaly            

8.4.4.2.3.      Neuropathic Pain

8.4.4.2.4.    Alzheimer’s Disease

8.4.4.2.5.    Cognitive Disorder         

8.4.4.2.6.    Dementia            

8.4.4.2.7.    Diabetic Retinopathy              

8.4.4.2.8.    Gastrointestinal Tumor

8.4.4.2.9.    Neuroendocrine Tumors            

8.4.4.2.10.  Pancreatic Tumor            

8.4.4.2.11.  Pituitary ACTH Hypersecretion

8.4.5.   Italy

8.4.5.1.    Italy Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

8.4.5.1.1.    CNTX-0290

8.4.5.1.2.    NNC-26910

8.4.5.1.3.     Veldoreotide

8.4.5.2.    Italy Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

8.4.5.2.1.    Chronic Pain

8.4.5.2.2.    Acromegaly            

8.4.5.2.3.      Neuropathic Pain

8.4.5.2.4.    Alzheimer’s Disease

8.4.5.2.5.    Cognitive Disorder         

8.4.5.2.6.    Dementia            

8.4.5.2.7.    Diabetic Retinopathy              

8.4.5.2.8.    Gastrointestinal Tumor

8.4.5.2.9.    Neuroendocrine Tumors             

8.4.5.2.10.  Pancreatic Tumor            

8.4.5.2.11.  Pituitary ACTH Hypersecretion

8.4.6.   Rest of Europe

8.4.6.1.    Rest of Europe Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

8.4.6.1.1.    CNTX-0290

8.4.6.1.2.    NNC-26910

8.4.6.1.3.     Veldoreotide

8.4.6.2.    Rest of Europe Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

8.4.6.2.1.    Chronic Pain

8.4.6.2.2.    Acromegaly            

8.4.6.2.3.      Neuropathic Pain

8.4.6.2.4.    Alzheimer’s Disease

8.4.6.2.5.    Cognitive Disorder         

8.4.6.2.6.    Dementia            

8.4.6.2.7.    Diabetic Retinopathy              

8.4.6.2.8.    Gastrointestinal Tumor

8.4.6.2.9.    Neuroendocrine Tumors            

8.4.6.2.10.  Pancreatic Tumor            

8.4.6.2.11.  Pituitary ACTH Hypersecretion

8.5.   Key Segment for Channeling Investments

8.5.1.   By Country

8.5.2.   By Type

8.5.3.   By Application

9.    Asia Pacific Somatostatin Receptor Type 4 Market Analysis and Forecasts, 2018 – 2026

9.1.   Overview

9.1.1.   Asia Pacific Market Revenue (US$ Mn)

9.2.   Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Type

9.2.1.   CNTX-0290

9.2.2.   NNC-26910

9.2.3.    Veldoreotide

9.3.   Asia Pacific Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

9.3.1.   Chronic Pain

9.3.2.   Acromegaly            

9.3.3.     Neuropathic Pain

9.3.4.   Alzheimer’s Disease

9.3.5.   Cognitive Disorder         

9.3.6.   Dementia            

9.3.7.   Diabetic Retinopathy              

9.3.8.   Gastrointestinal Tumor

9.3.9.   Neuroendocrine Tumors            

9.3.10. Pancreatic Tumor            

9.3.11. Pituitary ACTH Hypersecretion

9.4.   Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Country

9.4.1.   China

9.4.1.1.    China Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

9.4.1.1.1.    CNTX-0290

9.4.1.1.2.    NNC-26910

9.4.1.1.3.     Veldoreotide

9.4.1.2.    China Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

9.4.1.2.1.    Chronic Pain

9.4.1.2.2.    Acromegaly            

9.4.1.2.3.      Neuropathic Pain

9.4.1.2.4.    Alzheimer’s Disease

9.4.1.2.5.    Cognitive Disorder         

9.4.1.2.6.    Dementia            

9.4.1.2.7.    Diabetic Retinopathy              

9.4.1.2.8.    Gastrointestinal Tumor

9.4.1.2.9.    Neuroendocrine Tumors            

9.4.1.2.10.  Pancreatic Tumor            

9.4.1.2.11.  Pituitary ACTH Hypersecretion

9.4.2.   Japan

9.4.2.1.    Japan Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

9.4.2.1.1.    CNTX-0290

9.4.2.1.2.    NNC-26910

9.4.2.1.3.     Veldoreotide

9.4.2.2.    Japan Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

9.4.2.2.1.    Chronic Pain

9.4.2.2.2.    Acromegaly            

9.4.2.2.3.      Neuropathic Pain

9.4.2.2.4.    Alzheimer’s Disease

9.4.2.2.5.    Cognitive Disorder         

9.4.2.2.6.    Dementia            

9.4.2.2.7.    Diabetic Retinopathy              

9.4.2.2.8.    Gastrointestinal Tumor

9.4.2.2.9.    Neuroendocrine Tumors            

9.4.2.2.10.  Pancreatic Tumor            

9.4.2.2.11.  Pituitary ACTH Hypersecretion

9.4.3.   India

9.4.3.1.    India Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

9.4.3.1.1.    CNTX-0290

9.4.3.1.2.    NNC-26910

9.4.3.1.3.     Veldoreotide

9.4.3.2.    India Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

9.4.3.2.1.    Chronic Pain

9.4.3.2.2.    Acromegaly            

9.4.3.2.3.      Neuropathic Pain

9.4.3.2.4.    Alzheimer’s Disease

9.4.3.2.5.    Cognitive Disorder         

9.4.3.2.6.    Dementia            

9.4.3.2.7.    Diabetic Retinopathy              

9.4.3.2.8.    Gastrointestinal Tumor

9.4.3.2.9.    Neuroendocrine Tumors            

9.4.3.2.10.  Pancreatic Tumor            

9.4.3.2.11.  Pituitary ACTH Hypersecretion

9.4.4.   Southeast Asia

9.4.4.1.    Southeast Asia Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

9.4.4.1.1.    CNTX-0290

9.4.4.1.2.    NNC-26910

9.4.4.1.3.     Veldoreotide

9.4.4.2.    Southeast Asia Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

9.4.4.2.1.    Chronic Pain

9.4.4.2.2.    Acromegaly            

9.4.4.2.3.      Neuropathic Pain

9.4.4.2.4.    Alzheimer’s Disease

9.4.4.2.5.    Cognitive Disorder         

9.4.4.2.6.    Dementia            

9.4.4.2.7.    Diabetic Retinopathy              

9.4.4.2.8.    Gastrointestinal Tumor

9.4.4.2.9.    Neuroendocrine Tumors            

9.4.4.2.10.  Pancreatic Tumor            

9.4.4.2.11.  Pituitary ACTH Hypersecretion

9.4.5.   Rest of Asia Pacific

9.4.5.1.    Rest of Asia Pacific Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

9.4.5.1.1.    CNTX-0290

9.4.5.1.2.    NNC-26910

9.4.5.1.3.     Veldoreotide

9.4.5.2.    Rest of Asia Pacific Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

9.4.5.2.1.    Chronic Pain

9.4.5.2.2.    Acromegaly            

9.4.5.2.3.      Neuropathic Pain

9.4.5.2.4.    Alzheimer’s Disease

9.4.5.2.5.    Cognitive Disorder         

9.4.5.2.6.    Dementia            

9.4.5.2.7.    Diabetic Retinopathy               

9.4.5.2.8.    Gastrointestinal Tumor

9.4.5.2.9.    Neuroendocrine Tumors            

9.4.5.2.10.  Pancreatic Tumor            

9.4.5.2.11.  Pituitary ACTH Hypersecretion

9.5.   Key Segment for Channeling Investments

9.5.1.   By Country

9.5.2.   By Type

9.5.3.   By Application

10. Middle East and Africa Somatostatin Receptor Type 4 Market Analysis and Forecasts, 2018 – 2026

10.1. Overview

10.1.1. Middle East and Africa Market Revenue (US$ Mn)

10.2. Middle East and Africa Market Revenue (US$ Mn) and Forecasts, By Type

10.2.1. CNTX-0290

10.2.2. NNC-26910

10.2.3.  Veldoreotide

10.3. Middle East and Africa Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

10.3.1. Chronic Pain

10.3.2. Acromegaly            

10.3.3.   Neuropathic Pain

10.3.4. Alzheimer’s Disease

10.3.5. Cognitive Disorder         

10.3.6. Dementia            

10.3.7. Diabetic Retinopathy              

10.3.8. Gastrointestinal Tumor

10.3.9. Neuroendocrine Tumors            

10.3.10.   Pancreatic Tumor            

10.3.11.   Pituitary ACTH Hypersecretion

10.4. Middle East and Africa Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. GCC Countries

10.4.1.1.  GCC Countries Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

10.4.1.1.1.  CNTX-0290

10.4.1.1.2.  NNC-26910

10.4.1.1.3.   Veldoreotide

10.4.1.2.  GCC Countries Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

10.4.1.2.1.  Chronic Pain

10.4.1.2.2.  Acromegaly            

10.4.1.2.3.    Neuropathic Pain

10.4.1.2.4.  Alzheimer’s Disease

10.4.1.2.5.  Cognitive Disorder         

10.4.1.2.6.  Dementia            

10.4.1.2.7.  Diabetic Retinopathy              

10.4.1.2.8.  Gastrointestinal Tumor

10.4.1.2.9.  Neuroendocrine Tumors            

10.4.1.2.10.  Pancreatic Tumor            

10.4.1.2.11.  Pituitary ACTH Hypersecretion

10.4.2. Southern Africa

10.4.2.1.  Southern Africa Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

10.4.2.1.1.  CNTX-0290

10.4.2.1.2.  NNC-26910

10.4.2.1.3.   Veldoreotide

10.4.2.2.  Southern Africa Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

10.4.2.2.1.  Chronic Pain

10.4.2.2.2.  Acromegaly            

10.4.2.2.3.    Neuropathic Pain

10.4.2.2.4.  Alzheimer’s Disease

10.4.2.2.5.  Cognitive Disorder         

10.4.2.2.6.  Dementia            

10.4.2.2.7.  Diabetic Retinopathy              

10.4.2.2.8.  Gastrointestinal Tumor

10.4.2.2.9.  Neuroendocrine Tumors            

10.4.2.2.10.  Pancreatic Tumor            

10.4.2.2.11.  Pituitary ACTH Hypersecretion

10.4.3. Rest of MEA

10.4.3.1.  Rest of MEA Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

10.4.3.1.1.  CNTX-0290

10.4.3.1.2.  NNC-26910

10.4.3.1.3.   Veldoreotide

10.4.3.2.  Rest of MEA Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

10.4.3.2.1.  Chronic Pain

10.4.3.2.2.  Acromegaly            

10.4.3.2.3.    Neuropathic Pain

10.4.3.2.4.  Alzheimer’s Disease

10.4.3.2.5.  Cognitive Disorder         

10.4.3.2.6.  Dementia            

10.4.3.2.7.  Diabetic Retinopathy              

10.4.3.2.8.  Gastrointestinal Tumor

10.4.3.2.9.  Neuroendocrine Tumors            

10.4.3.2.10.  Pancreatic Tumor            

10.4.3.2.11.  Pituitary ACTH Hypersecretion

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Type

10.5.3. By Application

11. Latin America Somatostatin Receptor Type 4 Market Analysis and Forecasts, 2018 – 2026

11.1. Overview

11.1.1. Latin America Market Revenue (US$ Mn)

11.2. Latin America Market Revenue (US$ Mn) and Forecasts, By Type

11.2.1. CNTX-0290

11.2.2. NNC-26910

11.2.3.  Veldoreotide

11.3. Latin America Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

11.3.1. Chronic Pain

11.3.2. Acromegaly            

11.3.3.   Neuropathic Pain

11.3.4. Alzheimer’s Disease

11.3.5. Cognitive Disorder         

11.3.6. Dementia            

11.3.7. Diabetic Retinopathy              

11.3.8. Gastrointestinal Tumor

11.3.9. Neuroendocrine Tumors            

11.3.10.   Pancreatic Tumor            

11.3.11.   Pituitary ACTH Hypersecretion

11.4. Latin America Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. Brazil

11.4.1.1.  Brazil Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

11.4.1.1.1.  CNTX-0290

11.4.1.1.2.  NNC-26910

11.4.1.1.3.   Veldoreotide

11.4.1.2.  Brazil Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

11.4.1.2.1.  Chronic Pain

11.4.1.2.2.  Acromegaly            

11.4.1.2.3.    Neuropathic Pain

11.4.1.2.4.  Alzheimer’s Disease

11.4.1.2.5.  Cognitive Disorder         

11.4.1.2.6.  Dementia            

11.4.1.2.7.  Diabetic Retinopathy              

11.4.1.2.8.  Gastrointestinal Tumor

11.4.1.2.9.  Neuroendocrine Tumors            

11.4.1.2.10.  Pancreatic Tumor            

11.4.1.2.11.  Pituitary ACTH Hypersecretion

11.4.2. Rest of Latin America

11.4.2.1.  Rest of Latin America Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Type

11.4.2.1.1.  CNTX-0290

11.4.2.1.2.  NNC-26910

11.4.2.1.3.   Veldoreotide

11.4.2.2.  Rest of Latin America Somatostatin Receptor Type 4 Market Revenue (US$ Mn) and Forecasts, By Application

11.4.2.2.1.  Chronic Pain

11.4.2.2.2.  Acromegaly             

11.4.2.2.3.    Neuropathic Pain

11.4.2.2.4.  Alzheimer’s Disease

11.4.2.2.5.  Cognitive Disorder         

11.4.2.2.6.  Dementia            

11.4.2.2.7.  Diabetic Retinopathy              

11.4.2.2.8.  Gastrointestinal Tumor

11.4.2.2.9.  Neuroendocrine Tumors            

11.4.2.2.10.  Pancreatic Tumor            

11.4.2.2.11.  Pituitary ACTH Hypersecretion

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Type

11.5.3. By Application

12. Competitive Benchmarking

12.1. Player Positioning Analysis

12.2. Global Presence and Growth Strategies

13. Player Profiles

13.1. Centrexion Therapeutics

13.1.1. Company Details

13.1.2. Company Overview

13.1.3. Product Offerings

13.1.4. Key Developments

13.1.5. Financial Analysis

13.1.6. SWOT Analysis

13.1.7. Business Strategies

13.2. CRINETICS PHARMACEUTICALS

13.2.1. Company Details

13.2.2. Company Overview

13.2.3. Product Offerings

13.2.4. Key Developments

13.2.5. Financial Analysis

13.2.6. SWOT Analysis

13.2.7. Business Strategies

13.3. Strongbridge Biopharma plc

13.3.1. Company Details

13.3.2. Company Overview

13.3.3. Product Offerings

13.3.4. Key Developments

13.3.5. Financial Analysis

13.3.6. SWOT Analysis

13.3.7. Business Strategies

 

 Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

At Absolute Markets Insights, we use both top-down and bottom-up approach for calculating the market estimates and market forecast data. We allocate year-on-year growth rate from 2018 to 2026 and reach to the calculations for the global CAGR. Basically for estimation of the products and applications, usually we follow bottom-up approach, where we track the trends in different regions and their countries. We track down the growth factors, restraints, rules & regulations and opportunities for each country  and its region and finally calculate the global numbers. We first track the growth for the U.S. and Rest of North America. With these factors we can estimate the growth and trend for North America, similar approach would be taken for Europe, Asia Pacific, Latin America and Middle East & Africa. Finally, through our home grown model we reach to estimation and forecasting of the global numbers.   

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends. 

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

 

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 204

    Backtrace:

    File: /home/absolute/public_html/application/views/pages/reportpage.php
    Line: 204
    Function: _error_handler

    File: /home/absolute/public_html/application/controllers/Report.php
    Line: 153
    Function: view

    File: /home/absolute/public_html/index.php
    Line: 315
    Function: require_once